NVAX Stock Rises Ahead Of Q2 Earnings As Focus Shifts To Licensing Deals

Novavax will release Q2 2026 financial results before U.S. market open on Thursday.

Stock rises ahead of earnings, with focus on licensing deals.

Licensing deals are seen as key to Novavax's future growth.